专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016176462A1 METHODS AND COMPOSITIONS FOR THERANOSTIC NANOPARTICLES 审中-公开
标题翻译：治疗纳米颗粒的方法和组合物
公开(公告)号：WO2016176462A1
公开(公告)日：2016-11-03
申请号：PCT/US2016/029804
申请日：2016-04-28
申请人： UNIVERSITY OF CENTRAL FLORIDA FOUNDATION, INC. , SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AT LAKE NONA , MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： KHALED, Annette , PEREZ FIGUEROA, Jesus Manuel , SANTRA, Santimukul , KAITTANIS, Charalambos , SANTIESTEBAN, Oscar , GRIMM, Jan , SESSIONS, Hampton
IPC分类号： C07K7/00 , A61P35/00
CPC分类号： A61K47/6869 , A61K38/08 , A61K38/10 , A61K45/06 , A61K47/6935 , A61K51/1072 , A61K51/1244
摘要： Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.
摘要翻译：公开了用于鉴定实体瘤细胞靶的组合物和方法。还公开了用于治疗前列腺癌的组合物和方法。此外，公开了包含CT20p的癌症治疗组合物。公开了与作为固体肿瘤特异性细胞蛋白质的底物的靶向配体缀合的纳米颗粒。

2. 发明申请

WO2014055097A1 ANDROGEN SUPPRESSION, PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND THE CONCEPT OF CONDITIONALLY ENHANCED VULNERABILITY 审中-公开
标题翻译：安定剂抑制，前列腺特异性抗原和有条件增强的易感性的概念
公开(公告)号：WO2014055097A1
公开(公告)日：2014-04-10
申请号：PCT/US2013/000069
申请日：2013-03-14
申请人： CORNELL UNIVERSITY
发明人： BANDER, Neil, H.
IPC分类号： C07K16/30
CPC分类号： C07K16/40 , A61K49/0008 , A61K51/1072 , A61K2039/505 , C07K16/3069 , C12Q1/6886 , G01N33/57434 , G01N33/57492
摘要： Anti-androgen therapies represent the cornerstone of prostate cancer (PC) treatment. Yet all PC patients ultimately fail efforts to rein in the androgen receptor (AR). This invention is based on the discovery that prostate-specific membrane antigen (PSMA), a highly PC-specific and clinically validated cell surface target, is AR-suppressed and up-regulated in PC as a result of hormonal manipulation. This up-regulation occurs in an unexpected timeframe and it occurs even in the castrate-resistant setting. As a result, hormonal therapy creates a state of conditionally enhanced vulnerability of PC to PSMA-targeted anti-cancer/cytotoxic agents that can be exploited by leveraging anti-AR therapy by the addition of PSMA-targeted agents. We demonstrate this conditionally enhanced vulnerability in a castrate-resistant animal model. The state of conditionally enhanced vulnerability may be relevant for other cancer targets and efforts to screen for them may improve other cancer therapies.
摘要翻译：抗雄激素疗法是前列腺癌（PC）治疗的基石。然而，所有PC患者最终都不能努力控制雄激素受体（AR）。本发明基于以下发现：由于激素操作，PC中的前列腺特异性膜抗原（PSMA）是高度PC特异性和临床验证的细胞表面靶，其被AR抑制和上调。这种上调发生在意想不到的时间内，即使在阉割的环境中也会发生。因此，荷尔蒙治疗产生有条件地增强PC对PSMA靶向抗癌/细胞毒性剂的脆弱性的状态，可以通过添加PSMA靶向药物来利用抗AR治疗来开发。我们在阉割动物模型中证明了这种有条件地增强的脆弱性。有条件增强脆弱性的状态可能与其他癌症靶点相关，并且筛选它们的努力可能会改善其他癌症治疗。

3. 发明申请

WO2013061083A3 THERAPEUTIC AGENTS AND USES THEREOF 审中-公开
标题翻译：治疗药剂及其用途
公开(公告)号：WO2013061083A3
公开(公告)日：2013-06-27
申请号：PCT/GB2012052675
申请日：2012-10-26
申请人： FREDAX AB , SMITH STEPHEN EDWARD
发明人： STRAND SVEN-ERIK , TRAN AMANDA THUY , AXELSSON SVEN-NIKLAS ANDERS
IPC分类号： A61K51/10 , A61P35/00 , C07K16/30 , G01N33/574
CPC分类号： A61K51/1072 , A61K47/6803 , A61K49/16 , A61K49/221 , A61K51/1018 , A61K51/1075 , A61K51/1093 , A61K51/1096 , C07K16/18 , C07K16/3069 , C07K16/40 , C07K2317/565 , G01N33/57434 , G01N2333/96455
摘要： The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
摘要翻译：本申请提供了一种包含或组成具有对用于治疗前列腺癌的激肽释放酶蛋白（例如PSA或hK2）的特异性的结合部分的药剂，以及用于治疗患者中前列腺癌的方法，方法包括给患者施用治疗有效量的包含结合部分或由激肽释放酶蛋白的特异性组成的试剂。

4. 发明申请

WO2011098611A2 ALPHA-EMITTING COMPLEXES 审中-公开
标题翻译： ALPHA发射复合物
公开(公告)号：WO2011098611A2
公开(公告)日：2011-08-18
申请号：PCT/EP2011/052158
申请日：2011-02-14
申请人： ALGETA AS , RAMDAHL, Thomas
发明人： RAMDAHL, Thomas
IPC分类号： A61K51/10 , A61K51/04 , A61P35/00
CPC分类号： A61K51/0478 , A61K51/1045 , A61K51/1051 , A61K51/1072 , A61K51/1093
摘要： The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
摘要翻译：本发明提供了一种组织靶向复合物，其包含组织靶向部分，含有八齿羟基吡啶酮的配体和α发射钍放射性核素的离子。本发明另外提供了使用这种复合物的治疗方法，其生产和使用方法，以及包含这种复合物的试剂盒和药物组合物。

5. 发明申请

WO2007059082A1 METHOD OF TREATING OVARIAN AND RENAL CANCER USING ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN 审中-公开
标题翻译：使用抗T细胞免疫球蛋白域和MUCIN域1（TIM-1）抗原的抗体治疗卵巢癌和肾癌的方法
公开(公告)号：WO2007059082A1
公开(公告)日：2007-05-24
申请号：PCT/US2006/044090
申请日：2006-11-13
申请人： CURAGEN CORPORATION , TSE, Kam, Fai , POLLACK, Vincent, A. , MACDOUGALL, John , SHENOY, Suresh, G. , MANSFIELD, Traci , LICHENSTEIN, Henri , JEFFERS, Michael, E. , LAROCHELLE, William, J.
发明人： TSE, Kam, Fai , POLLACK, Vincent, A. , MACDOUGALL, John , SHENOY, Suresh, G. , MANSFIELD, Traci , LICHENSTEIN, Henri , JEFFERS, Michael, E. , LAROCHELLE, William, J.
IPC分类号： A61K51/00 , G01N33/53 , A61K39/395 , C12N5/06 , C07K16/46
CPC分类号： C07K16/18 , A61K47/48469 , A61K47/48561 , A61K47/48607 , A61K47/48638 , A61K47/48746 , A61K47/6825 , A61K47/6849 , A61K47/6861 , A61K47/6869 , A61K47/6897 , A61K51/1027 , A61K51/106 , A61K51/1072 , A61K2039/505 , B82Y5/00 , C07K16/2803 , C07K16/2809 , C07K16/3038 , C07K16/3069 , C07K16/42 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/57438 , G01N33/57449 , G01N2333/705
摘要： The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR' s) and/or complementarity determining regions (CDR' s), specifically from FRl through FR4 or CDRl through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要翻译：本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体用于治疗癌症（例如肾癌和卵巢癌）的用途。特别地，提供针对抗原TIM-1的完全人单克隆抗体。编码分离的多核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1到FR4或CDR1到CDR3。还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

6. 发明申请

WO2006125481A1 MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN 审中-公开
标题翻译：单克隆抗体和单链抗体片段抗细胞表面前体特异性膜抗原
公开(公告)号：WO2006125481A1
公开(公告)日：2006-11-30
申请号：PCT/EP2006/001917
申请日：2006-03-02
申请人： UNIVERSITÄTSKLINIKUM FREIBURG , ELSÄSSER-BEILE, Ursula , WOLF, Philipp , GIERSCHNER, Dorothee , BÜHLER, Patrick , WETTERAUER, Ulrich
发明人： ELSÄSSER-BEILE, Ursula , WOLF, Philipp , GIERSCHNER, Dorothee , BÜHLER, Patrick , WETTERAUER, Ulrich
IPC分类号： C12N15/13 , A61K47/48 , C07K16/30
CPC分类号： C07K16/3069 , A61K47/6869 , A61K51/1072 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/77 , C07K2317/80 , C07K2317/92
摘要： Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
摘要翻译：分离的单克隆抗体或其抗原结合部分结合肿瘤细胞表面上出现的天然形式的前列腺特异性膜抗原，其特征在于其与标记或细胞毒性剂连接或构建为双特异性抗体的一部分，或重组双抗体。

7. 发明申请

WO2004098535A3 MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF 审中-公开
标题翻译：前列腺特异性抗原抗体的修饰抗体及其用途
公开(公告)号：WO2004098535A3
公开(公告)日：2005-07-14
申请号：PCT/US2004006586
申请日：2004-03-03
申请人： MILLENNIUM PHARM INC , HORVATH CHRISTOPHER J , WEBB IAIN J
发明人： HORVATH CHRISTOPHER J , WEBB IAIN J
IPC分类号： A61K20060101 , A61K39/395 , A61K47/48 , A61K51/10 , C07K16/30
CPC分类号： C07K16/30 , A61K45/06 , A61K47/6851 , A61K47/6869 , A61K51/1045 , A61K51/1072 , A61K2039/505 , A61K2039/545 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/56
摘要： Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
摘要翻译：提供了修饰抗体或其抗原结合片段到人前列腺特异性膜抗原（PSMA）的细胞外结构域。修饰的抗PSMA抗体或其抗原结合片段与其给定物种（例如人）的未修饰对应物相比，具有较少的免疫原性。还公开了包含上述抗体，核酸，重组表达载体和用于制备此类抗体和片段的宿主细胞的药物组合物。还提供了使用本发明的抗体来检测人类PSMA或者在体外或体内烧伤或杀死表达PSMA的细胞例如表达PSMA的癌症或前列腺细胞的方法。

8. 发明申请

WO2004098535A9 MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF 审中-公开
标题翻译：用于前列腺特异性膜抗原的修饰的抗体及其用途
公开(公告)号：WO2004098535A9
公开(公告)日：2005-02-24
申请号：PCT/US2004006586
申请日：2004-03-03
申请人： MILLENNIUM PHARM INC , HORVATH CHRISTOPHER J , WEBB IAIN J
发明人： HORVATH CHRISTOPHER J , WEBB IAIN J
IPC分类号： A61K20060101 , A61K39/395 , A61K47/48 , A61K51/10 , C07K16/30 , A61K
CPC分类号： C07K16/30 , A61K45/06 , A61K47/6851 , A61K47/6869 , A61K51/1045 , A61K51/1072 , A61K2039/505 , A61K2039/545 , C07K16/3069 , C07K2317/14 , C07K2317/24 , C07K2317/56
摘要： Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
摘要翻译：提供了修饰的抗体或其抗原结合片段与人前列腺特异性膜抗原（PSMA）的胞外结构域的结合。与其对给定物种例如人的未修饰的对应物相比，修饰的抗PSMA抗体或其抗原结合片段已经变得免疫原性较低。还公开了包含上述抗体，核酸，重组表达载体和用于制备此类抗体和片段的宿主细胞的药物组合物。还提供了使用本发明的抗体检测人PSMA或体外或体内消除或杀死表达PSMA的细胞（例如表达PSMA的癌症或前列腺细胞）的方法。

9. 发明申请

WO02096948A3 ENGINEERED TETRAVALENT ANTIBODIES AND METHODS OF USE 审中-公开
标题翻译：工程化四项抗体及其使用方法
公开(公告)号：WO02096948A3
公开(公告)日：2003-08-07
申请号：PCT/US0202374
申请日：2002-01-29
申请人： IDEC PHARMA CORP , BRASLAWSKY GARY R , HANNA NABIL , CHINN PAUL , HARIHARAN KANDASAMY
发明人： BRASLAWSKY GARY R , HANNA NABIL , CHINN PAUL , HARIHARAN KANDASAMY
IPC分类号： A61K47/48 , A61K51/10 , A61P35/00 , C07K16/00 , C07K16/28 , C07K16/30 , C12N15/85 , C12P21/02 , A61K39/395
CPC分类号： C12P21/02 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6901 , A61K51/1027 , A61K51/1045 , A61K51/1072 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/52 , C07K2319/00 , C12N15/85
摘要： Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H>4 4
摘要翻译：提供了包含用于治疗肿瘤，自身免疫或其它病症的二聚抗体的方法，组合物和试剂盒。本发明的二聚体抗体可以包含具有相同抗原结合特异性（同源二聚体）的两个抗体分子（H> 4 <4>），或者可以包含两个不同抗体分子，其具有对两种不同抗原的结合特异性（异二聚体）。在优选的实施方案中，包含二聚体的抗体分子是非共价缔合的。

10. 发明申请

WO0243570A3 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES 审中-公开
标题翻译：使用抗C3B（i）抗体预防和治疗癌症的方法
公开(公告)号：WO0243570A3
公开(公告)日：2003-07-10
申请号：PCT/US0144813
申请日：2001-11-28
申请人： UNIV VIRGINIA
发明人： TAYLOR RONALD , NARDIN ALESSANDRA , SUTHERLAND WILLIAM M , SOKOLOFF MITCHELL H , CHUNG LELAND W K
IPC分类号： A61K48/00 , A61K35/16 , A61K38/00 , A61K39/395 , A61K51/10 , A61P13/10 , A61P31/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/44 , C07K16/46
CPC分类号： A61K39/395 , A61K38/00 , A61K48/00 , A61K51/1072 , C07K16/18 , C07K16/2896 , C07K16/3069 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2319/00 , A61K2300/00
摘要： The present invetion relates to mehtods of treating and preventing cancer in an animal comprising administrating to said animal antibodies specific for C3b(i). The present invention also realtes to mehtods of treating and preventing cancer in an animal comprising administering to said animal IgG antbodies, IgM antibodies and/or complement components in combination with antibodies immunospecifically bind to one or more cancer cell antigens in combination with antibodies immunospecific for C3b(i). The present invention further relates to pharmaceutical compositions for the treatment and prevention of cancer comprising one or more antibodies immunospecific for C3b(i) and one or more antibodies immunospecific for one or more cancer cell antigens.
摘要翻译：本发明涉及在动物中治疗和预防癌症的方法，包括给予针对C3b（i）特异的所述动物抗体。本发明还涉及治疗和预防动物癌症的方法，包括向所述动物IgG抗体施用IgM抗体和/或补体组分与抗体免疫特异性结合一种或多种癌细胞抗原与C3b免疫特异性结合（一世）。本发明进一步涉及用于治疗和预防癌症的药物组合物，其包含针对C3b（i）免疫特异性的一种或多种抗体和针对一种或多种癌细胞抗原免疫特异性的一种或多种抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式